Cempra, Inc. Receives U.S. Orphan Drug Designation for Taksta™ for Treatment of Prosthetic Joint Infections

Published: Oct 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHAPEL HILL, N.C.,, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate Taksta™ (CEM-102) for the treatment of prosthetic joint infections (PJI). The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Taksta is Cempra's oral loading dose formulation of fusidic acid, an orally-active anti-staphylococcal agent with a long history of safety and efficacy outside of the U.S.

Help employers find you! Check out all the jobs and post your resume.

Back to news